Big News, page-18

Of course, you are aware that the humanitarian side of RAP's opportunities is really a drop in the bucket compared to the revenue they can potentially raise in the Western and Asian markets.

Also in post FDA/C-Mark approval stages, as it changes its apparent Global market share from 0.25% to .5%, to 1% to 2%, to 4%, it's revenue doubles in every stage. There is no way this will be priced at a PE of 30 for a long long time time...there are plenty of less exciting companies trading on the ASX atm with no PE at all and yet far bigger market caps than RAP.

Again, I say this based on the assumption that we get regulatory approval, and that the market will be as interested in the product, as the large institutional investors are interested in RAP right now.

I sense though, that if management aim to do another small CR to pursue the Asian markets, they would prefer that things cool down a bit with slow steady gains, slip back under the radar and stabilise as it is hard to suggest good discounted value to Insto's if the chart resembles a roller coaster.

CT